299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04458129 (ClinicalTrials.gov)	July 8, 2020	30/6/2020	Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis	EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN	Cystic Fibrosis	Drug: Treatment with polyethylene glycol (Macrogol 4000)	University Hospital, Bordeaux	NULL	Not yet recruiting	4 Years	17 Years	All	23	Phase 2	NULL
2	EUCTR2019-004958-29-FR (EUCTR)	07/04/2020	04/06/2020	Polyethylene glycol and intestinal inflammation in cystic fibrosis	EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN - MUCOLAX	Cystic fibrosis MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: FORLAX 4 g, poudre pour solution buvable en sachet	CHU de Bordeaux	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	23	Phase 2	France
3	NCT04210427 (ClinicalTrials.gov)	December 12, 2019	18/12/2019	Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit	Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit	Cystic Fibrosis Gastrointestinal Disease	Drug: Polyethylene Glycol 3350;Device: SmartPill Motility System & PillCam Patency Capsule	St. Louis University	NULL	Recruiting	18 Years	40 Years	All	15	Phase 4	United States